BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 30779082)

  • 1. SP1-induced upregulation of long noncoding RNA LINC00313 contributes to papillary thyroid cancer progression via the miR-422a.
    Yan DG; Liu N; Chao M; Tu YY; Liu WS
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1134-1144. PubMed ID: 30779082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA LINC00313 modulates papillary thyroid cancer tumorigenesis via sponging miR-4429.
    Wu WJ; Yin H; Hu JJ; Wei XZ
    Neoplasma; 2018 Nov; 65(6):933-942. PubMed ID: 29940766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing long non-coding RNAs nicotinamide nucleotide transhydrogenase antisense RNA 1 inhibited papillary thyroid cancer cell proliferation, migration and invasion and promoted apoptosis via targeting miR-199a-5p.
    Wang D; Zheng Y
    Endocr J; 2021 May; 68(5):583-597. PubMed ID: 33612561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
    Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
    Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA SNHG22 increases ZEB1 expression via competitive binding with microRNA-429 to promote the malignant development of papillary thyroid cancer.
    Gao H; Sun X; Wang H; Zheng Y
    Cell Cycle; 2020 May; 19(10):1186-1199. PubMed ID: 32306838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA SAMMSON promotes papillary thyroid carcinoma progression through p300/Sp1 axis and serves as a novel diagnostic and prognostic biomarker.
    Shao L; Sun W; Wang Z; Dong W; Qin Y
    IUBMB Life; 2020 Feb; 72(2):237-246. PubMed ID: 31478331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor.
    Feng K; Liu Y; Xu LJ; Zhao LF; Jia CW; Xu MY
    Biomed Pharmacother; 2018 Aug; 104():686-698. PubMed ID: 29803929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-146b-5p Regulates the Expression of Long Noncoding RNA
    Peng Y; Fang X; Yao H; Zhang Y; Shi J
    Cancer Biother Radiopharm; 2021 Jun; 36(5):433-440. PubMed ID: 32343601
    [No Abstract]   [Full Text] [Related]  

  • 9. Positive feedback loop SP1/SNHG1/miR-199a-5p promotes the malignant properties of thyroid cancer.
    Ding W; Zhao S; Shi Y; Chen S
    Biochem Biophys Res Commun; 2020 Feb; 522(3):724-730. PubMed ID: 31791587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lncRNA SNHG3 accelerates papillary thyroid carcinoma progression via the miR-214-3p/PSMD10 axis.
    Sui G; Zhang B; Fei D; Wang H; Guo F; Luo Q
    J Cell Physiol; 2020 Oct; 235(10):6615-6624. PubMed ID: 32048306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA LINC00460 promotes the papillary thyroid cancer progression by regulating the LINC00460/miR-485-5p/Raf1 axis.
    Li G; Kong Q
    Biol Res; 2019 Dec; 52(1):61. PubMed ID: 31870440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA XIST Promotes Migration and Invasion of Papillary Thyroid Cancer Cell by Modulating MiR-101-3p/CLDN1 Axis.
    Du YL; Liang Y; Cao Y; Liu L; Li J; Shi GQ
    Biochem Genet; 2021 Apr; 59(2):437-452. PubMed ID: 33057875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
    Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
    J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression.
    Cai X; Zhao Z; Dong J; Lv Q; Yun B; Liu J; Shen Y; Kang J; Li J
    Cell Death Dis; 2019 Feb; 10(3):184. PubMed ID: 30796202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
    Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
    Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HOTAIRM1/miR-107/TDG axis regulates papillary thyroid cancer cell proliferation and invasion.
    Li D; Chai L; Yu X; Song Y; Zhu X; Fan S; Jiang W; Qiao T; Tong J; Liu S; Fan L; Lv Z
    Cell Death Dis; 2020 Apr; 11(4):227. PubMed ID: 32269214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-577 inhibits papillary thyroid carcinoma cell proliferation, migration and invasion by targeting SphK2.
    Xue KC; Hu DD; Zhao L; Li N; Shen HY
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3794-3800. PubMed ID: 28975989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA LINC00152 promotes cell growth and invasion of papillary thyroid carcinoma by regulating the miR-497/BDNF axis.
    Sun Z; Guo X; Zang M; Wang P; Xue S; Chen G
    J Cell Physiol; 2019 Feb; 234(2):1336-1345. PubMed ID: 30146756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
    Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
    Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA LINC00520 accelerates progression of papillary thyroid carcinoma by serving as a competing endogenous RNA of microRNA-577 to increase Sphk2 expression.
    Sun Y; Shi T; Ma Y; Qin H; Li K
    Cell Cycle; 2020 Apr; 19(7):787-800. PubMed ID: 32075502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.